Advances in the design and development of SARS-CoV-2 vaccines
XL Peng, JSY Cheng, HL Gong, MD Yuan… - Military Medical …, 2021 - Springer
Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA …
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
ABSTRACT Introduction The Coronavirus Disease 2019 (COVID-19) pandemic has caused
devastating human and economic costs. Vaccination is an important step in controlling the …
devastating human and economic costs. Vaccination is an important step in controlling the …
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and …
R Thiruvengadam, A Awasthi, G Medigeshi… - The Lancet Infectious …, 2022 - thelancet.com
Background SARS-CoV-2 variants of concern (VOCs) have threatened COVID-19 vaccine
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
R Vikkurthi, A Ansari, AR Pai, SN Jha, S Sachan… - Nature …, 2022 - nature.com
BBV152 is a whole-virion inactivated vaccine based on the Asp614Gly variant. BBV152 is
the first alum-imidazoquinolin-adjuvanted vaccine authorized for use in large populations …
the first alum-imidazoquinolin-adjuvanted vaccine authorized for use in large populations …
Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models
R Choque-Guevara, A Poma-Acevedo… - Plos one, 2022 - journals.plos.org
COVID-19 pandemic has accelerated the development of vaccines against its etiologic
agent, SARS-CoV-2. However, the emergence of new variants of the virus lead to the …
agent, SARS-CoV-2. However, the emergence of new variants of the virus lead to the …
[HTML][HTML] Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt
S Agarwal, S Kaur, TR Asuru, G Joshi… - Clinical and …, 2022 - ncbi.nlm.nih.gov
Dear Editor, In order to combat the COVID-19 pandemic, an extensive effort is being made
by researchers around the world to develop therapeutics against Severe Acute Respiratory …
by researchers around the world to develop therapeutics against Severe Acute Respiratory …
Antigenic epitope screening and functional modification of mannose enhance the efficacy of largemouth bass virus subunit vaccines
YJ Jia, JY Xia, FY Jiang, Y Li, G Chen… - Journal of Fish …, 2022 - Wiley Online Library
Major capsid protein (MCP) can be used as a subunit vaccine against largemouth bass virus
(LMBV). However, subunit vaccines usually have low immunogenicity. Here, to identify the …
(LMBV). However, subunit vaccines usually have low immunogenicity. Here, to identify the …
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG …
Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve
vaccine coverage in low-and middle-income countries. To this end, subunit-based …
vaccine coverage in low-and middle-income countries. To this end, subunit-based …
Designed SARS‐CoV‐2 receptor binding domain variants form stable monomers
M Klausberger, NF Kienzl, G Stadlmayr… - Biotechnology …, 2022 - Wiley Online Library
The receptor binding domain (RBD) of the SARS‐CoV‐2 spike (S)‐protein is a prime target
of virus‐neutralizing antibodies present in convalescent sera of COVID‐19 patients and thus …
of virus‐neutralizing antibodies present in convalescent sera of COVID‐19 patients and thus …
Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus
P Murugavelu, R Perween, T Shrivastava… - International …, 2021 - Elsevier
The spike protein of the SARS-CoV-2 virus is the foremost target for the designing of
vaccines and therapeutic antibodies and also acts as a crucial antigen in the assessment of …
vaccines and therapeutic antibodies and also acts as a crucial antigen in the assessment of …